Novasep is a major player in CDMO in the development and manufacture of small complex molecules mainly for pharmaceutical and biotechnology customers. The company operates a wide range of differentiated technologies, including high energy and cryogenic chemistries and industrial scale chromatography. It is a world leader in ADCs and HPAPIs, rapidly growing targeted cancer therapy segments.
Novasep’s capabilities are highly complementary to PharmaZell’s expertise in manufacturing complex APIs requiring special handling procedures or technologies. The combination of the two companies would create a leading, highly diverse and highly differentiated API and CDMO manufacturing platform. The combined business would be able to leverage a comprehensive and broad technology suite for complex molecules and a global production footprint to support pharmaceutical and biotech customers throughout a drug‘s lifecycle. The combined activity would generate nearly 500 million euros in turnover and employ nearly 2,000 people across seven production and R&D sites in Europe (Germany, France and Italy), two sites in India and one in the United States.
The proposed transaction would be supported by PharmaZell’s current majority shareholder, Bridgepoint. Bridgepoint Group PLC is the world’s leading listed private asset growth investor focused on the mid-market with € 27 billion in assets under management and a local presence in the United States, Europe and China.
The planned acquisition remains subject to the fulfillment of the usual conditions precedent for this type of transaction, in particular the information and consultation of works councils and other regulatory authorizations.
The press release is available in pdf.
Photo – https://mma.prnewswire.com/media/1628012/Novasep_PharmaZell.jpg
Logo – https://mma.prnewswire.com/media/1628011/Novasep_Passion_Smart_Processes_Logo.jpg
PDF – https://mma.prnewswire.com/media/1628027/PharmaZell_Novasep_ENG.pdf